The Sarah Cannon Research Institute-United Kingdom Drug Development Programme offers consistent performance and excellence through:

- A dedicated, experienced oncology drug development team
- State-of-the-art clinical trials unit in central London
- Competitive start-up timelines
- Rapid patient accrual via a large referral network

**Our Facility**

Our 13,000-square-foot facility is located within a registered historic building on Harley Street in London, England. It is a purpose-designed unit complete with 12 treatment chairs/beds and is conveniently located by three main rail stations and the Tube.

- CQC-registered oncology trials unit
- On-site pharmacy
- PK testing facilities
- -20 & -80°C freezers
- Refrigerated and non-refrigerated centrifuges
- Cardiac monitoring
- Access to hospital-based critical care services

**For Patients**

- Broad clinical trials portfolio (solid and haematological malignancies)
- Patient-centred support services
- Private areas for treatment
- On-site catering for patients
- Wireless internet and individual patient entertainment systems

**Study Metrics**

- Over 50 trials initiated across all study phases and tumour types since inauguration
- Pre-screened > 500 patients for rare mutations, amplifications or other genetic alterations
- 100 patients enrolled onto trials in 2013

**For Partners**

We are committed to our partners’ goals, and we tailor our teams and processes to meet them, ensuring strong science and consistent quality every step of the way. As collaborators, we strive to provide superior medical, scientific and operational insight that contribute to discovery and success.
Dr Hendrik-Tobias Arkenau, PhD, Director, Drug Development Programme, Sarah Cannon Research Institute-UK, has vast experience in early oncology clinical drug development (Phase I-II) with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research Institute UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.

Contact Information:
Phone: +44 (0) 203 219 5251 • Tobias.Arkenau@SarahCannonResearch.co.uk

Matthew Simmons, Head of Drug Development Programme, Sarah Cannon Research Institute-UK, has extensive operational and commercial experience across all phases of drug development within the pharmaceutical and CRO industries. He has overall responsibility for the day-to-day management of the Sarah Cannon Research Institute-UK Drug Development Programme. Mr. Simmons received his degree in molecular biology from The University of Manchester in 1994, and joined what was then SmithKline Beecham, working on the clinical development of a novel cytotoxic agent. Immediately before joining Sarah Cannon Research Institute-UK, he managed the global commercial operations teams for Worldwide Clinical Trials, a mid-sized, full-service- CRO.

Contact Information:
Phone: +44 (0) 203 219 5252 • Matthew.Simmons@SarahCannonResearch.co.uk